GLUE · CIK 0001826457
What Monte Rosa Therapeutics, Inc. told the SEC could break it.
Monte Rosa Therapeutics' disclosures are those of a pre-product biotech reliant on outside capital and a thin supply base. It has lost money since inception — net losses of $38.6 million in 2025 against a $477.2 million accumulated deficit — and expects increasing operating losses, leaving it dependent on further financing and milestone receipts. Its drug substance and drug product come from a small number of suppliers, in some cases sole-source, limiting its ability to scale supply for development and any eventual commercial demand, and it flags 2025 U.S. tariffs on Canada, Mexico, the EU, and China — plus retaliation — as a macro risk to operations that span Boston and Basel.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Liquidity & debt
- accumulated deficit $477.2M / ongoing lossesmedium
Monte Rosa is pre-product and has incurred losses since inception — net losses of $38.6M (2025) and $72.7M (2024) and a $477.2M accumulated deficit — and expects continued, increasing operating losses, making it dependent on further financing and milestone receipts.
“we had an accumulated deficit of $477.2 million as of December 31, 2025. For the years ended December 31, 2025 and 2024, we reported net losses of $38.6 million and $72.7 million, respectively.”
SEC filing →As of 2026
Sole-source dependency
- drug substance & drug product from few/sole suppliersmedium
Monte Rosa's drug substance and drug product are supplied by a small number of suppliers, in some cases sole-source — limiting its ability to scale supply for development and any eventual commercial demand.
“The drug substance and drug product in our product candidates are supplied to us from a small number of suppliers, and in some cases sole source suppliers.”
SEC filing →As of 2026
Regulatory & policy
- 2025 US tariffs / trade tensionslow
Monte Rosa flags 2025 US tariffs on Canada, Mexico, the EU and China (and retaliatory measures) as a macro risk that could disrupt trade and economic conditions affecting its operations (which span Boston and Basel, Switzerland).
“in 2025, the United States imposed tariffs on imports on its trading partners, including Canada, Mexico, the EU and China. Historically, tariffs have led to increased trade and political tensions. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“up to $2.1 billion in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies... We and Novartis also agreed to a net profit and loss sharing arrangement, in which we will co-fund any global clinical development from Phase 3 onwards and will share 30% of any profits and losses associated with the manufacturing and commercialization of”
Cited →Roche Holding AG
“Goods and services that we are required to provide to Roche and Novartis under these agreements are accounted for under ASC 606.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch